ARCT-021
| Vaccine description | |
|---|---|
| Target disease | COVID-19 |
| Type | mRNA |
| Clinical data | |
| Synonyms | Arcturus COVID-19 Vaccine, LUNAR-COV19 |
| Routes of administration | Intramuscular |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
|
International response |
|
Medical response |
|
ARCT-021, more commonly known as the LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
Development
Phase I-II
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[1] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[2] LUNAR-COV19 clinical trials in humans began in July 2020.[3]
On 4 January 2021, Arcturus Therapeutics initially start the clinical trial phase 2.[4]
References
- ↑ "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.
- ↑ "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. 2020-05-06. Retrieved 2020-05-08.
- ↑ "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. Retrieved 2020-07-27.
- ↑ "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. January 4, 2021. Retrieved January 17, 2021.
External links
This article "ARCT-021" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ARCT-021. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
